Tetulomab tetraxetan Lu-177
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tetulomab tetraxetan Lu-177
- DrugBank Accession Number
- DB12227
- Background
Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 697.81
Monoisotopic: 697.310511915 - Chemical Formula
- C30H47N7O10S
- Synonyms
- 177Lu-tetraxetan-tetulomab
- 177Lu-tetulomab
- Anti-CD37 antibody tetulomab tetraxetan Lu-177
- Betalutin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Pentacarboxylic acids and derivatives
- Direct Parent
- Pentacarboxylic acids and derivatives
- Alternative Parents
- N-phenylthioureas / L-alpha-amino acids / Aralkylamines / Trialkylamines / Thioureas / Amino acids / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 3 more
- Substituents
- Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group show 19 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6QU69VIG75
- CAS number
- Not Available
- InChI Key
- RMJFCRKHOJOLIN-CGAIIQECSA-N
- InChI
- InChI=1S/C30H47N7O10S/c31-24(29(46)47)3-1-2-8-32-30(48)33-22-6-4-21(5-7-22)15-23-16-36(19-27(42)43)12-11-34(17-25(38)39)9-10-35(18-26(40)41)13-14-37(23)20-28(44)45/h4-7,23-24H,1-3,8-20,31H2,(H,38,39)(H,40,41)(H,42,43)(H,44,45)(H,46,47)(H2,32,33,48)/t23?,24-/m0/s1
- IUPAC Name
- (2S)-2-amino-6-{[(4-{[1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-2-yl]methyl}phenyl)carbamothioyl]amino}hexanoic acid
- SMILES
- N[C@@H](CCCCNC(=S)NC1=CC=C(CC2CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN2CC(O)=O)C=C1)C(O)=O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Follicular Lymphoma ( FL) / Non-Hodgkin's Lymphoma (NHL) / Relapsed Follicular Lymphoma 1 1 Completed Treatment Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL) 1 1 Withdrawn Treatment Non-Hodgkin's Lymphoma (NHL) 1 1, 2 Completed Treatment Follicular Lymphoma ( FL) / Non-Hodgkin's Lymphoma (NHL) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.14 mg/mL ALOGPS logP -1.2 ALOGPS logP -6.8 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 1.07 Chemaxon pKa (Strongest Basic) 9.97 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 249.54 Å2 Chemaxon Rotatable Bond Count 17 Chemaxon Refractivity 179.77 m3·mol-1 Chemaxon Polarizability 72.8 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 237.50482 predictedDeepCCS 1.0 (2019) [M+H]+ 239.81065 predictedDeepCCS 1.0 (2019) [M+Na]+ 245.63545 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:40 / Updated at December 01, 2022 11:27